Market: NASD |
Currency: USD
Address: 3650 Gilmore Way
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Show more
📈 Xenon Pharmaceuticals Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$54.76
-
Upside/Downside from Analyst Target:
43.59%
-
Broker Call:
37
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2025-11-11
-
EPS Estimate:
-1.16
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Xenon Pharmaceuticals Inc.
| Date | Reported EPS |
|---|
| 2025-11-10 (estimated upcoming) | - |
| 2025-08-11 | -1.07 |
| 2025-05-12 | -0.83 |
| 2025-02-27 | -0.84 |
| 2024-11-12 | -0.81 |
| 2024-08-08 | -0.75 |
| 2024-05-09 | -0.62 |
| 2024-02-29 | -0.64 |
| 2023-11-08 | -0.73 |
| 2023-08-09 | -0.72 |
| 2023-05-09 | -0.63 |
| 2023-03-01 | -0.57 |
| 2022-11-08 | -0.57 |
| 2022-08-09 | -0.55 |
| 2022-05-10 | -0.35 |
| 2022-03-01 | -0.48 |
| 2021-11-10 | -0.36 |
| 2021-08-11 | -0.51 |
| 2021-05-11 | -0.42 |
| 2021-03-01 | -0.34 |
| 2020-11-05 | -0.25 |
| 2020-08-05 | - |
| 2020-05-21 | -0.22 |
| 2020-03-08 | -0.41 |
| 2019-11-05 | -0.33 |
📰 Related News & Research
No related articles found for "xenon pharmaceuticals".
